Lentinan-based Adjuvant Development

Lentinan-based Adjuvant Development

Unlike traditional adjuvants, polysaccharide-based adjuvants have good biocompatibility and low toxicity. Therefore, more and more scientists are turning to polysaccharide-based adjuvants. Lentinan (LNT) has been used as an immune adjuvant for vaccines due to its immunostimulatory properties. CD BioGlyco is a leader in the development of LNT adjuvant for diverse applications. We have been recognized by scientists from different countries for our first-class experimental capabilities and advanced Glyco™ Vaccine Development Platform.


Lentinus edodes is the second largest edible mushroom in the world and is also a traditional Chinese herbal medicine. LNT is the main active ingredient of Lentinus edodes and is composed of β-1,3-glucose hexasaccharide with β-1,6-branches. LNT has immunomodulatory, anti-infective, anti-tumor, and anti-viral effects. It has no immune-promoting effect on the normal body but improves the immune response of the body after infection. LNT is a special immune-enhancing adjuvant directed by thymus-dependent T cells and involving macrophages. It promotes the production of interleukins and the function of mononuclear macrophages. Therefore, LNTs are widely used in immune regulation.

Lentinan-based Adjuvant DevelopmentFig.1 Functional lentinan. (Trivedi, 2022)

Immune Properties of LNT

It has been reported that LNT combined with Bacille Calmette-Guérin (BCG) vaccine enhanced the killing ability of guinea pig alveolar macrophages against Mycobacterium tuberculosis and Gluconococcus aureus. Sulfated LNT increased chicken serum antibody titers and promoted lymphocyte proliferation, and was a more effective adjuvant than unmodified LNT. A synthetic LNT analog (β-glu6), when administered intraperitoneally in mice with hepatitis B surface antigen (HBsAg), increased B and T cell immune responses to the antigen. β-Glu6 promoted dendritic cell (DC) recruitment and maturation and enhanced antigen-specific CD4+ and CD8 numbers.

LNT Adjuvant Development Services

At present, studies have demonstrated the importance of LNT in vaccine adjuvants. After LNT is extracted from Lentinus edodes, new LNT-based adjuvants can be developed by modification. According to the customers' application needs, CD BioGlyco provides different types of LNT-based adjuvants development services. The services we provide include but are not limited to:

  • LNT adjuvant development to enhance the immune activity of BCG vaccine
  • Sulfated LNT adjuvant development
  • LNT analogs development such as β-glu6 adjuvant
  • LNT-modified calcium carbonate microparticles (CaCO3-LNT) adjuvant development

CD BioGlyco has extensive experience in developing LNT adjuvants by various modifications. Our systematic development platform and state-of-the-art development technology bring convenience to our global customers. If you have development needs for LNT adjuvants, please contact us directly and we will be more than happy to work with you on your project.


  1. Petrovsky, N.; Cooper, P.D. Carbohydrate-based immune adjuvants. Expert review of vaccines. 2011, 10(4):523-537.
  2. Trivedi, S.; et al. Functional polysaccharide lentinan: role in anti-cancer therapies and management of carcinomas. Pharmacological Research-Modern Chinese Medicine. 2022.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.